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Reply
We appreciate the comments of Dr. Spodick on our study (1). We
agree that atrial fibrillation is uncommonly associated with pericarditis,
but we believe that there is a relationship between these two conditions
in some patients. Many investigators in this field (2–7) also recognize
such an association between atrial fibrillation and pericarditis. In a
704-patient study by Davidson et al. (7), pericarditis was reported as
the only identifiable condition association with atrial fibrillation in 5
patients (0.7%). We found a similar magnitude of association (3 of 356
patients, 0.8%) in our study. In one of our patients, there was also a
history of systemic hypertension, a disorder more commonly associated
with atrial fibrillation. In the other two patients (a 27-year old man and
a 71-year old woman), no other underlying condition was identified.
Given the low incidence of atrial fibrillation with pericarditis, we agree
with Dr. Spodick that, for these patients, exclusion of occult cardiac
disease is also prudent.
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Interstitial Fibrosis and Angiotensin-
Converting Enzyme Inhibition in Patients
With End-Stage Myocardial Infarction
Marijianowski et al. (1) have recently investigated the collagen content
of noninfarcted myocardium in patients with end-stage myocardial
infarction. They report that total collagen levels and collagen type I/III
ratios did not differ statistically from those in reference hearts of
patients who died of noncardiovascular-related disease. This outcome
contrasts with other studies in humans (2–6) and experimental animals
(7–10), which have demonstrated an increased interstitial fibrosis in
the remote myocardium after infarction and its contribution in the
impairment of systolic and diastolic ventricular function (11). How-
ever, all patients enrolled in the study of Marijianowski et al. (1) had
been treated with angiotensin-converting enzyme (ACE) inhibitors
(among other medications), which are known to cause an attenuation
of fibrogenesis (3,7,9). Therefore, it is hard to understand that the
authors consider it unlikely that ACE inhibition had been truly
effective on interstitial fibrosis. Their consideration is based on the
argument that other criteria of ventricular remodeling (“extensive
myocardial scar formation, with compensatory hypertrophy of viable
myocardium and global LV dilation”) were still present in these
patients.
No quantitative analysis or comparison of these “other criteria” has
been presented in this study. Also, it is questionable if, and to what
extent, the attenuation of fibrogenesis by ACE inhibition parallels its
effects on myocyte hypertrophy during the development of heart
failure: the triggers for an increase of interstitital collagen and for
myocyte hypertrophy are not the same under all circumstances (4,12)
and vice versa the effects of ACE inhibition differ in both processes
(12). Finally, we would like to comment upon the authors’ interpreta-
tion of the results obtained by other groups (see their Discussion). In
response to our own study (4), their qualification of microscopic
collagenous patches (our Fig. 1A) as “replacement fibrosis” indicative
of extended scarring is incorrect for at least two reasons: (1) we
excluded such extensions into our noninfarcted myocardial samples
microscopically and (2) even if present, isolated microscopic patches of
fibrosis are more likely caused by myocyte necrosis due to other
mechanisms (13,14).
In conclusion, we regard the results reported by Marijianowski et
al. (1) as new evidence that treatment with ACE inhibitors leads to an
attenuated interstitial fibrosis in noninfarcted myocardium of patients
with (end-stage) myocardial infarction.
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